An investigation on behalf of investors of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares over potential securities laws violations by Supernus Pharmaceuticals and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) concerning whether a series of statements by Supernus Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Rockville, MD based Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.

Supernus Pharmaceuticals Inc reported that its annual Total Revenue rose from $147.47 million in 2015 to $215 million in 2016 and that its Net Income rose from $13.94 million in 2015 to $91.22 million in 2016.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) grew from $11.29 per share in ealry 2016 to as high as $49.65 per share on September 18, 2017.

On September 18, 2017, Supernus Pharmaceuticals Inc announced interim results for its first Phase 3 clinical trial for SPN-810. In the same release, Supernus announced it would eliminate the 18mg dose arm.

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) declined on September 20, 2017 to $36.75 per share.